Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group

Ying Ying Leung, Ana-Maria Orbai, William Tillett, Alexis Ogdie, Lihi Eder, Niti Goel, Pil Hojgaard, Richard Holland, Ashish J. Mathew, Christine A. Lindsay, Anna Antony, Jeffrey Chau, Robin Christensen, Laura C. Coates, Philip J. Mease, Vibeke Strand, Oliver FitzGerald, Maarten de Wit, Kristina Callis Duffin and Dafna D. Gladman
The Journal of Rheumatology March 2021, jrheum.201679; DOI: https://doi.org/10.3899/jrheum.201679
Ying Ying Leung
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ying Ying Leung
Ana-Maria Orbai
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana-Maria Orbai
William Tillett
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for William Tillett
Alexis Ogdie
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexis Ogdie
Lihi Eder
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lihi Eder
Niti Goel
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Niti Goel
Pil Hojgaard
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pil Hojgaard
Richard Holland
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Holland
Ashish J. Mathew
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ashish J. Mathew
Christine A. Lindsay
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Antony
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Antony
Jeffrey Chau
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Christensen
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robin Christensen
Laura C. Coates
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura C. Coates
Philip J. Mease
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philip J. Mease
Vibeke Strand
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vibeke Strand
Oliver FitzGerald
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Oliver FitzGerald
Maarten de Wit
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maarten de Wit
Kristina Callis Duffin
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kristina Callis Duffin
Dafna D. Gladman
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. The authors are members of the Outcome Measures in Rheumatology (OMERACT), an organization that develops and validates outcome measures in rheumatology randomized controlled trials and longitudinal observational studies and receives arms-length funding from 36 sponsors. YYL is funded by the Clinician Scientist award of the National Medical Research Council, Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award, the Staurulakis Family Discovery Award, the Rheumatology Research Foundation, and the National Institutes of Health (NIH) through the Rheumatic Diseases Resource-based Core Center (P30-AR053503, Cores A and D; and P30-AR070254, Cores A and B). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the NIH, the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), or the Rheumatology Research Foundation (RRF). AO is funded by the Rheumatology Research Foundation and NIH/NIAMS K23 AR063764 and R01 AR072363. RC (the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). AJM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Y.Y. Leung, MB ChB, MD, Associate Professor, Duke-NUS Medical School, and Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; A.M. Orbai, MD, MHS, Assistant Professor of Medicine, Director, Psoriatic Arthritis Program, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; W. Tillett, BSc, MB ChB, PhD, MRCP, Consultant Rheumatologist, Senior Lecturer, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; A. Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; N. Goel, MD, Patient Research Partner, Consultant, Caduceus Biomedical Consulting, LLC, and Adjunct Assistant Professor, Duke University School of Medicine, Durham, North Carolina, USA; P. Hojgaard, MD, PhD, Department of Rheumatology, Holbaek Hospital, Holbaek, and the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; R. Holland, MBBS, Concord Repatriation General Hospital, Sydney, Australia; A.J. Mathew, MBBS, DNB, DM, Associate Professor in Rheumatology, Christian Medical College, Vellore, India and Clinical Research Fellow, Psoriatic Arthritis Program, University Health Network, University of Toronto, Toronto, Ontario, Canada; C.A. Lindsay, PharmD, Patient Research Partner, VP Professional and Advocacy Relations, Aurinia Pharma U.S., Inc., Rockville, Maryland, USA; A. Antony, MBBS, Monash University School of Clinical Sciences, Monash Medical Centre, Clayton, Melbourne, Australia; J. Chau, GRAPPA Patient Research Partner, Hong Kong; R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Professor of Biostatistics and Clinical Epidemiology, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; L.C. Coates, MB ChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA; V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; O. FitzGerald, MD, FRCPI, FRCP(UK), Consultant Rheumatologist and Newman Clinical Research Professor, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; M. de Wit, PhD, Patient Research Partner, Amsterdam, The Netherlands; K. Callis Duffin, MD, MS, Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. LE has been on advisory boards or received educational/research grants from Novartis, UCB, Eli Lily, Pfizer, and Janssen. There are no conflicts of interest from other co-authors. This paper does not require institutional review board approval. Address correspondence to Dr. Y.Y. Leung, Department of Rheumatology and Immunology, Singapore General Hospital, 20 College Road, The Academia, Singapore. Email: katyccc@hotmail.com.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dafna D. Gladman
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)–Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Working Group provided updates at the 2020 GRAPPA annual meeting on its work toward developing a core outcome set for PsA. Working groups were set up for the 4 prioritized domains: enthesitis, fatigue, structural damage, and physical function. Two instruments for measurement of physical function were provisionally endorsed: (1) the Health Assessment Questionnaire–Disability Index and (2) the physical functioning domain in the Medical Outcomes Study 36-item Short Form survey.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 50, Issue 1
1 Jan 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group
Ying Ying Leung, Ana-Maria Orbai, William Tillett, Alexis Ogdie, Lihi Eder, Niti Goel, Pil Hojgaard, Richard Holland, Ashish J. Mathew, Christine A. Lindsay, Anna Antony, Jeffrey Chau, Robin Christensen, Laura C. Coates, Philip J. Mease, Vibeke Strand, Oliver FitzGerald, Maarten de Wit, Kristina Callis Duffin, Dafna D. Gladman
The Journal of Rheumatology Mar 2021, jrheum.201679; DOI: 10.3899/jrheum.201679

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group
Ying Ying Leung, Ana-Maria Orbai, William Tillett, Alexis Ogdie, Lihi Eder, Niti Goel, Pil Hojgaard, Richard Holland, Ashish J. Mathew, Christine A. Lindsay, Anna Antony, Jeffrey Chau, Robin Christensen, Laura C. Coates, Philip J. Mease, Vibeke Strand, Oliver FitzGerald, Maarten de Wit, Kristina Callis Duffin, Dafna D. Gladman
The Journal of Rheumatology Mar 2021, jrheum.201679; DOI: 10.3899/jrheum.201679
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
  • Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases
  • The Positive Predictive Value of a Very High Serum IgG4 Concentration for the Diagnosis of IgG4-Related Disease
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire